Elite in Autoimmune Hemolytic Anemia

Bernd Jilma

Vienna, AT 
Elite in Autoimmune Hemolytic Anemia
Vienna, AT 
OverviewLocationsClinical Research

Overview

Bernd Jilma practices in Vienna, Austria. Mr. Jilma is rated as an Elite expert by MediFind in the treatment of Autoimmune Hemolytic Anemia. His top areas of expertise are Autoimmune Hemolytic Anemia, Disseminated Intravascular Coagulation, Sepsis, Thrombectomy, and Kidney Transplant.

His clinical research consists of co-authoring 357 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 20 articles and participated in 4 clinical trials in the study of Autoimmune Hemolytic Anemia.

Gender
Male

Locations

Vienna, Austria
Other Locations
Poland, Austria
Meidling, Austria

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD)
A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD)
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: Pegcetacoplan
Study Phase: Phase 3
Safety, Tolerability and Efficacy of Monoclonal CD38 Antibody Felzartamab in Late Antibody-Mediated Renal Allograft Rejection - A Phase 2 Pilot Trial
Safety, Tolerability and Efficacy of Monoclonal CD38 Antibody Felzartamab in Late Antibody-Mediated Renal Allograft Rejection - A Phase 2 Pilot Trial
Enrollment Status: Completed
Publish Date: April 18, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Placebo-controlled, Double-blind, Single-ascending-dose and Multiple-ascending-dose, Phase 1 Study to Assess the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of IV NTR-441 Solution in HV Adults and COVID-19 Patients
A Randomized, Placebo-controlled, Double-blind, Single-ascending-dose and Multiple-ascending-dose, Phase 1 Study to Assess the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of IV NTR-441 Solution in HV Adults and COVID-19 Patients
Enrollment Status: Terminated
Publish Date: January 19, 2024
Intervention Type: Drug
Study Drug: NTR-441
Study Phase: Phase 1
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion
Enrollment Status: Completed
Publish Date: December 23, 2022
Intervention Type: Drug
Study Drug: Sutimlimab
Study Phase: Phase 3
A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion
A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion
Enrollment Status: Completed
Publish Date: October 31, 2022
Intervention Type: Drug
Study Drug: Sutimlimab
Study Phase: Phase 3
Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement-mediated Disorders. A Single/Multiple Ascending Dose Phase 1 Study.
Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement-mediated Disorders. A Single/Multiple Ascending Dose Phase 1 Study.
Enrollment Status: Completed
Publish Date: April 25, 2022
Intervention Type: Drug, Other
Study Phase: Phase 1
A Prospective Randomized, Double Blind Study on Safety and Efficacy of Alprostadil as Additional Anticoagulant in Patients With Veno- Venous Extracorporeal Membrane Oxygenation (ECMO)
A Prospective Randomized, Double Blind Study on Safety and Efficacy of Alprostadil as Additional Anticoagulant in Patients With Veno- Venous Extracorporeal Membrane Oxygenation (ECMO)
Enrollment Status: Terminated
Publish Date: February 09, 2022
Intervention Type: Drug
Study Phase: Phase 2
Phase 2 Clinical Trial of the BioMed rTSST-1 Variant Vaccine in Healthy Adults
Phase 2 Clinical Trial of the BioMed rTSST-1 Variant Vaccine in Healthy Adults
Enrollment Status: Completed
Publish Date: January 04, 2022
Intervention Type: Biological
Study Phase: Phase 2
Safety, Tolerability and Efficacy of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Rejection After Kidney Transplantation - a Pilot Trial
Safety, Tolerability and Efficacy of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Rejection After Kidney Transplantation - a Pilot Trial
Enrollment Status: Completed
Publish Date: September 09, 2020
Intervention Type: Drug
Study Phase: Phase 2
Vorapaxar in the Human Endotoxemia Model A Randomized, Double-Blind, Crossover Study
Vorapaxar in the Human Endotoxemia Model A Randomized, Double-Blind, Crossover Study
Enrollment Status: Completed
Publish Date: January 10, 2020
Intervention Type: Drug, Other
Study Phase: Phase 4
Defibrotide in the Human Endotoxemia Model -- an Exploratory Trial Investigating the Effects and the Mechanisms of Defibrotide
Defibrotide in the Human Endotoxemia Model -- an Exploratory Trial Investigating the Effects and the Mechanisms of Defibrotide
Enrollment Status: Completed
Publish Date: December 19, 2019
Intervention Type: Drug
Study Phase: Phase 4
Does Acetylsalicylic Acid Reduce the Mortality of Patients Admitted to an Intensive Care Unit
Does Acetylsalicylic Acid Reduce the Mortality of Patients Admitted to an Intensive Care Unit
Enrollment Status: Terminated
Publish Date: December 18, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 11 Less Clinical Trials

357 Total Publications

Taurolidine-induced Severe Anaphylaxis.
Taurolidine-induced Severe Anaphylaxis.
Journal: Kidney medicine
Published: October 06, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Jilma's expertise for a condition
ConditionClose
View All 17 Advanced Conditions
View All 43 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile